APL-9

APL-9 is an investigational, PEGylated synthetic cyclic peptide designed to centrally control the complement cascade at the level of complement component C3. It acts as a second-generation C3 inhibitor, sharing its mechanism of action with pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. APL-9 is intended for intravenous administration for acute use and has been developed primarily by Apellis Pharmaceuticals. Its main therapeutic rationale is to treat diseases caused by excessive or uncontrolled activation of the complement system, including acute interventions such as severe COVID-19 and potentially in settings like gene therapy-associated immune responses[1][2][3][5][6][8].

Other names

APL 9APL9APL-9